Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes.
作者信息
Takvorian Samuel U, Haas Naomi B
机构信息
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
出版信息
JAMA Netw Open. 2021 Jul 1;4(7):e2117159. doi: 10.1001/jamanetworkopen.2021.17159.
Abstract
摘要
相似文献
1
Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes.
JAMA Netw Open. 2021 Jul 1;4(7):e2117159. doi: 10.1001/jamanetworkopen.2021.17159.
2
Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:13-15. doi: 10.1111/ajco.13061.
3
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Cancer Treat Rev. 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Epub 2016 Feb 12.
4
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.
5
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
JAMA Netw Open. 2021 Jul 1;4(7):e2116536. doi: 10.1001/jamanetworkopen.2021.16536.
6
Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23.
7
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Epub 2014 Sep 17.
8
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
Clin Genitourin Cancer. 2015 Aug;13(4):e305-e309. doi: 10.1016/j.clgc.2014.11.008. Epub 2014 Nov 22.
9
Management of castrate-resistant prostate cancer in older men.
J Geriatr Oncol. 2016 Mar;7(2):57-63. doi: 10.1016/j.jgo.2016.01.001. Epub 2016 Feb 18.
10
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Oncology (Williston Park). 2015 Jun;29(6):416-23.
引用本文的文献
1
Machine learning in metastatic cancer research: Potentials, possibilities, and prospects.
Comput Struct Biotechnol J. 2023 Mar 29;21:2454-2470. doi: 10.1016/j.csbj.2023.03.046. eCollection 2023.
2
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.
Cancers (Basel). 2021 Sep 8;13(18):4522. doi: 10.3390/cancers13184522.
本文引用的文献
1
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
JAMA Netw Open. 2021 Jul 1;4(7):e2116536. doi: 10.1001/jamanetworkopen.2021.16536.
2
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):341-348. doi: 10.1038/s41391-020-00280-6. Epub 2020 Sep 3.
3
Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology.
JAMA Oncol. 2020 Jul 1;6(7):1104-1106. doi: 10.1001/jamaoncol.2020.0746.
4
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.
5
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
6
Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value.
J Clin Oncol. 2011 Mar 20;29(9):1095-8. doi: 10.1200/JCO.2010.33.5596. Epub 2011 Feb 22.
7
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82. doi: 10.1093/jnci/djh141.
Zotero 插件